Mountain View, CA – May 5, 2009 – REGiMMUNE Corporation today announced that a company abstract has been accepted for presentation at the 2009 American Transplant Congress (ATC, May 30 to June 3, 2009 in Boston, Massachusetts). The poster presentation is titled “Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus.” KRN7000 is a synthetic derivative of alpha-galactosylceramide, a small molecule that potently activates natural killer T (NKT) cells. RGI-2001, a proprietary liposomal formulation of KRN7000, is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute Graft-versus-Host disease (GvHD) associated with bone marrow transplantation later this year.
The material in this press release comes from the originating research organization. Content may be edited for style and length. Have a question? Let us know.
One email, each morning, with our latest posts. From medical research to space news. Environment to energy. Technology to physics.
Thank you for subscribing.
Something went wrong.